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Tackling antimicrobial resistance (AMR) is a priority of the
World Health Organization’s public health agenda, and in
November 2017 the organisation launched guidelines on the
use of medically important antimicrobials in the food production
industry. Their unambiguous recommendations were that their
routine use for animal growth promotion and disease prevention
in healthy animals should be discontinued (Boxed Text on page
2box 1).1 In line with the global action plan on AMR,2 the aim
is to help preserve the effectiveness of antimicrobials critical
for human medicine. As a supranational body, WHO has taken
the opportunity to put independent pressure on healthcare policy
makers to now respond to its challenge.
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Box 1Recommendations from WHO1
1.An overall reduction in use of all classes of
medically important antimicrobials in food
producing animals
2.Complete restriction of use of all classes of
medically important antimicrobials in food
producing animals for growth promotion
3.3 Complete restriction of use of all classes of
medically important antimicrobials in food
producing animals for prevention of infectious
diseases that have not yet been clinically
diagnosed
4.4a Suggest that antimicrobials classified as
critically important for human medicine should
not be used for control of the dissemination
of a clinically diagnosed infectious disease
identified within a group of food producing
animals
5.4b Suggest that antimicrobials classified as
highest priority (see below) critically important
for human medicine should not be used for
treatment of food producing animals with a
clinically diagnosed infectious disease
Evidence level (based on grade criteria) for 1, 2, and
3 is low, and for 4a and b is very low, reflecting the
lack of high quality studies
Highest priority critically important
antimicrobial: a critically important
antimicrobial belonging to an antimicrobial
class that meets three criteria:
1. It is used for treating infections in high
absolute numbers of humans, or is commonly
used in healthcare settings to treat patients
with serious bacterial infections for which the
antimicrobial class is the sole choice, or one
of few choices, to treat serious infections in
humans
2. It is often used for any indication in human
medicine, or else is commonly used in patients
with serious infections in healthcare settings
3. It is used to treat infections in humans for
which there is evidence of transmission of
resistant bacteria or resistance genes from
non-human sources to humans
A complete list of highest priority critically
important antimicrobials is available at www.
who.int/foodsafety/cia/en
Although the guidelines were welcomed by world leaders,3 some
organisations, particularly in the food producing industry,
including the US Department of Agriculture, considered it to
be too uncompromising and questioned the underpinning
evidence. Others said the recommendations were insufficiently
far reaching. A visibly more united interagency approach with
the UN’s Food and Agriculture Organisation and the World
Organisation for Animal Health could have strengthened the
message. Nonetheless, the recommendations are an important
step forward.
It is widely accepted that antimicrobial exposure is the single
most important driver for the emergence of, and increase in,
AMR.4 Moreover, AMR bacteria or AMR-encoding genes may
transfer from animals to humans through the environment, food
chain, or by direct contact. Despite this, in some countries as
much as 80% of the total consumption of antimicrobials is in
the animal sector, with marked variation across nations.5 6 Within
Europe, for example, use in Spain is over a 100-fold more per
production unit than in Norway.5 Emerging economies are
projected to increase their use of antimicrobials in livestock,
contributing to a projected global increase of 67% from 2010
to 2030.6
Some countries have already successfully reduced antimicrobial
use in livestock without compromising animal health or
productivity.1 7 The WHO guidelines do not restrict any required
treatment or the targeted prevention of specific diseases. An
accompanying policy brief gives guidance on implementation
and actions to preserve the effectiveness of antimicrobials in
veterinary medicine, including reduction targets, surveillance
measures, and improving nutrition, hygiene, infection
prevention, and the use of vaccines.1 Healthy animals need fewer
antimicrobials but many agricultural stakeholders see the push
to reduce antimicrobial consumption as unwarranted
interference, rather than a drive to improve animal health.
The new guidelines were shaped by published reviews
commissioned by the WHO Advisory Group on Integrated
Surveillance of AMR.8 9 This work reinforced the established
understanding that reducing antimicrobial use in agriculture is
associated with reductions in antimicrobial resistance in food
producing animals, as well as the idea that, at minimum, the
benefit appears to extend to farmers and those in direct contact
with food producing animals.9 The authors clearly acknowledge
the limitations in these reviews, and although there are few
studies showing a direct effect on human health of antimicrobial
use in animals, the overall body of evidence provided enough
evidence to support WHO’s recommendations.
The recommendations could have been more critical of the
evidence supporting use of antimicrobials as growth promoters.10
Moreover, the focus on specific antimicrobial classes rather
than a broader consideration of all antimicrobials could be
questioned, as the use of one class may select for resistance to
other classes, because of shared mechanisms of resistance and
genetically linked resistance determinants.
AMR is complex; different bacterial species, resistance
mechanisms, transferable plasmids, host populations, and
environmental reservoirs contribute to direct and indirect
transmission. Further studies to to characterise the spread of
AMR in both animals and humans are needed, supported by
more sophisticated methodology and technology.
Bacterial genome sequencing shows a complex emerging
picture, with evidence of an association between human
infections and reservoirs of antimicrobial resistance in animals.
Heavy use of colistin in Chinese livestock and the emergence
and spread of colistin resistance led to the banning of colistin
for growth promotion in China in November 2016.8 11
But we also need to maintain perspective. Successful
interventions to reduce antimicrobial use in livestock have not
always resulted in AMR reduction in humans, and molecular
studies of some bacterial species show that direct transmission
of the organism or the resistance genes from livestock to humans
may be less important than other sources, including
human-to-human transmission.12 WHO guidelines highlight the
need for further research to tackle knowledge gaps and improve
the quality of evidence, including more standardised
methodology, better surveillance, and higher quality data.
Eliminating the non-essential use of antimicrobials in livestock
is a rational and welcome response to the growing crisis in
AMR. The overarching aims fall within the generally agreed
principles of antimicrobial stewardship by veterinarians,
industry, and government. As countries are often reluctant to
phase out non-essential use, whether through uncertainty or
because of commercial pressures, the guidelines provide a
necessary external impetus. They may also encourage societal
response, consumer expectation, and civil action to drive and
sustain this agenda. Of course, action in animals must not
distract us from action within human healthcare—antimicrobial
stewardship, effective prevention of infections, and the need
for clean water and sanitation—but must been seen as an
essential additional requirement in our global response to AMR.
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